22-05-2025
Nexus Pharmaceuticals Launches Methylene Blue Injection
LINCOLNSHIRE, Ill., May 22, 2025--(BUSINESS WIRE)--Nexus Pharmaceuticals, LLC proudly announces the launch of Methylene Blue Injection, USP. Methylene Blue Injection is indicated for the treatment of methemoglobinemia – a condition that affects the blood's ability to carry oxygen.
"The launch represents a vital addition to Nexus' growing portfolio of life-saving and difficult-to-manufacture medications," said Usman Ahmed, CEO of Nexus Pharmaceuticals. "Methylene Blue is a critical drug in emergency care, and we're proud to contribute to the FDA-approved supply."
Nexus' Methylene Blue is available in cartons of five, single-dose 10 mL vials (5 mg/mL) (0.5%). Order through your Wholesaler or from Customer Service at (888) 806-4606.
Unit of Sale NDC: 14789-0119-05
- Cencora – 10299117- Cardinal – 5982525- McKesson – 3029428- Morris & Dickson – 609628
About Nexus Pharmaceuticals, LLC: Nexus Pharmaceuticals, LLC, a US-based healthcare company, specializes in innovative processes to make difficult-to-manufacture specialty and generic drugs that are easier to use, less labor intensive, and more streamlined in practice. Nexus ensures that its high-quality drug products fulfill a critical unmet medical need and deliver dependable life-saving treatment options when and where they're needed most.
View source version on
Contacts
Media Contact: Grace Conroygconroy@ (847) 527-7490
